Your session is about to expire
← Back to Search
Topical Gel
Patients with Granuloma Annulare for Granuloma Annulare
Phase 1
Waitlist Available
Led By William Damsky, M.D., Ph.D.
Research Sponsored by TWi Biotechnology, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1, day 14, day 42:pre-dose; day 28: pre-dose, 2 through 24 hours post-dose
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a special skin-applied gel called AC-1101 on patients with Granuloma Annulare, a specific skin condition. The gel likely works by reducing inflammation or changing the immune response in the skin.
Eligible Conditions
- Granuloma Annulare
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 1, day 14, day 42:pre-dose; day 28: pre-dose, 2 through 24 hours post-dose
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1, day 14, day 42:pre-dose; day 28: pre-dose, 2 through 24 hours post-dose
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in skin irritation using Dermal Rating Scale (DRS)
Incidence and proportion of subjects with treatment emergent adverse events (TEAEs), AEs and serious adverse events (SAEs).
Electrocardiogram
+4 moreSecondary study objectives
Apparent terminal half-life (T1/2) of AC-1101
Area under the plasma concentration-time curve from time 0 to extrapolated to infinity (AUC[0-infinity]) of AC-1101
Area under the plasma concentration-time curve from time 0 to last time of quantifiable concentration (AUC[0-t]) of AC-1101
+3 moreOther study objectives
Change in Dermatology Life Quality Index (DLQI)
Change in GA-Investigator Global Assessment (GA-IGA) score for the treated GA lesions
Change in Granuloma Annulare Severity and Morphology Instrument (GASMI) activity score for the treated GA lesions
+2 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Patients with Granuloma AnnulareExperimental Treatment1 Intervention
4-week treatment and 2-week follow-up period (without treatment)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AC-1101
2022
Completed Phase 1
~20
Find a Location
Who is running the clinical trial?
TWi Biotechnology, Inc.Lead Sponsor
9 Previous Clinical Trials
677 Total Patients Enrolled
William Damsky, M.D., Ph.D.Principal InvestigatorYale Department of Dermatology
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:Research Study Groups:
This trial has the following groups:- Group 1: Patients with Granuloma Annulare
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Granuloma Annulare Patient Testimony for trial: Trial Name: NCT05580042 — Phase 1
Share this study with friends
Copy Link
Messenger